Jubilant Life Sciences to raise Rs 350 crore via NCDs

27 Jun 2018 Evaluate

Jubilant Life Sciences has received approval to raise funds upto Rs 350 crore through issuance of redeemable Non-Convertible Debentures (NCDs) on private placement basis. The proposed issue has been rated ‘AA/Stable’ by CRISIL.

The proceeds would be mainly utilised for repayment of the existing debt and to reduce the overall cost of borrowing. The board of directors of the company at its meeting held on June 27, decided to obtain approval of the shareholders of the company.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions.

Jubilant Pharmova Share Price

837.15 -13.30 (-1.56%)
20-Mar-2026 12:25 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1770.80
Dr. Reddys Lab 1294.80
Cipla 1255.20
Zydus Lifesciences 888.20
Lupin 2310.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×